Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-83 |
Sentence |
denotes |
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. |
T1 |
0-83 |
Sentence |
denotes |
The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. |
T2 |
84-192 |
Sentence |
denotes |
Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to advanced liver diseases. |
T2 |
84-192 |
Sentence |
denotes |
Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to advanced liver diseases. |
T3 |
193-313 |
Sentence |
denotes |
Lack of effective pharmacotherapies for NASH is largely attributable to an incomplete understanding of its pathogenesis. |
T3 |
193-313 |
Sentence |
denotes |
Lack of effective pharmacotherapies for NASH is largely attributable to an incomplete understanding of its pathogenesis. |
T4 |
314-399 |
Sentence |
denotes |
The deubiquitinase cylindromatosis (CYLD) plays key roles in inflammation and cancer. |
T4 |
314-399 |
Sentence |
denotes |
The deubiquitinase cylindromatosis (CYLD) plays key roles in inflammation and cancer. |
T5 |
400-471 |
Sentence |
denotes |
Here we identified CYLD as a suppressor of NASH in mice and in monkeys. |
T5 |
400-471 |
Sentence |
denotes |
Here we identified CYLD as a suppressor of NASH in mice and in monkeys. |
T6 |
472-577 |
Sentence |
denotes |
CYLD is progressively degraded upon interaction with the E3 ligase TRIM47 in proportion to NASH severity. |
T6 |
472-577 |
Sentence |
denotes |
CYLD is progressively degraded upon interaction with the E3 ligase TRIM47 in proportion to NASH severity. |
T7 |
578-775 |
Sentence |
denotes |
We observed that overexpression of Cyld in hepatocytes concomitantly inhibits lipid accumulation, insulin resistance, inflammation and fibrosis in mice with NASH induced in an experimental setting. |
T7 |
578-775 |
Sentence |
denotes |
We observed that overexpression of Cyld in hepatocytes concomitantly inhibits lipid accumulation, insulin resistance, inflammation and fibrosis in mice with NASH induced in an experimental setting. |
T8 |
776-945 |
Sentence |
denotes |
Mechanistically, CYLD interacts directly with the kinase TAK1 and removes its K63-linked polyubiquitin chain, which blocks downstream activation of the JNK-p38 cascades. |
T8 |
776-945 |
Sentence |
denotes |
Mechanistically, CYLD interacts directly with the kinase TAK1 and removes its K63-linked polyubiquitin chain, which blocks downstream activation of the JNK-p38 cascades. |
T9 |
946-1154 |
Sentence |
denotes |
Notably, reconstitution of hepatic CYLD expression effectively reverses disease progression in mice with dietary or genetically induced NASH and in high-fat diet-fed monkeys predisposed to metabolic syndrome. |
T9 |
946-1154 |
Sentence |
denotes |
Notably, reconstitution of hepatic CYLD expression effectively reverses disease progression in mice with dietary or genetically induced NASH and in high-fat diet-fed monkeys predisposed to metabolic syndrome. |
T10 |
1155-1324 |
Sentence |
denotes |
Collectively, our findings demonstrate that CYLD mitigates NASH severity and identify the CYLD-TAK1 axis as a promising therapeutic target for management of the disease. |
T10 |
1155-1324 |
Sentence |
denotes |
Collectively, our findings demonstrate that CYLD mitigates NASH severity and identify the CYLD-TAK1 axis as a promising therapeutic target for management of the disease. |